Quest Diagnostics Incorporated (DGX) Stock: Price, Forecast & Analyst Target
Quest Diagnostics Incorporated (DGX) — MoonshotScore 74/100 (Strong band), calculated Nov 18, 2026. Price $258.99 (-0.27%), as of the Nov 19, 2026 trading session; market cap $28.5B. Expected results Feb 9, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Quest Diagnostics Incorporated · DGX · NYSE · Healthcare · Medical Diagnostics & Research
Research dated 2026-09-12: Quest Diagnostics turns patient specimens and clinical encounters into testing results, diagnostic information and related services for clinicians, hospitals, health plans, employers and patients. The case depends on whether rising demand through its laboratory and collection network can keep lifting profit and cash generation while a debt-heavy balance sheet limits room for disappointment.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Quest Diagnostics (DGX)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, though the balance sheet and growth are only middling; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- EPS beat 8 of the last 8 reports
- expected results Feb 9, 2027
- Altman Z 3.81 · Piotroski F 7
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 75 | Strong | |
| 76 | Strong | |
| 76 | Strong | |
| 76 | Strong | |
| 74 | Strong | |
| 74 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $258.99 | |
| Change on the day | -0.27% | |
| 52-week range | $171.18–$263.19 | |
| Market capitalisation | $28.5B | — |
| Price / earnings (trailing) | 25.18 | |
| Shares traded on the day | 892.4K | |
| Beta (volatility vs the S&P 500) | 0.55 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Quest Diagnostics (DGX): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens, Englander-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Quest Diagnostics (DGX), and what does it report?
Short answer · as of
Quest sells routine and advanced clinical testing, anatomic pathology, diagnostic information and related services.
Research dated 2026-09-12.
Its delivery system spans laboratories, patient service centers, in-office phlebotomists and mobile health professionals, while specialized brands serve pathology, insurance risk assessment and healthcare technology needs.
Reported revenue is overwhelmingly concentrated in Diagnostic Information Services. That makes test activity and the economics of collecting, processing and reporting results more important than the broad healthcare classification might suggest; this is primarily a scaled service network, not a drug-development pipeline.
What do the latest results show for Quest Diagnostics (DGX)?
Research dated 2026-09-12.
The latest period extended a broad operating advance: revenue, gross profit, operating income, net income and diluted earnings all rose from the preceding period. Operating cash flow also strengthened, while reported revenue and earnings continued their run above consensus expectations.
Management attributed the raised full-year outlook to growth momentum and continued interest in its lab insights. That explanation is management’s framing rather than a disclosed bridge from test volume, pricing or acquisitions, so the reported profit progression remains the firmer evidence.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $2.82B | $245M | $2.15 (diluted) |
| Q4 FY2025 | $2.81B | $245M | $2.19 (diluted) |
| Q1 FY2026 | $2.90B | $252M | $2.24 (diluted) |
| Q2 FY2026 | $3.04B | $320M | $2.85 (diluted) |
What are the financial strengths and risks for Quest Diagnostics (DGX)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Quest consistently generated operating cash after capital spending across the reported quarterly series, and the latest period paired stronger operating cash flow with a higher cash balance. Liquidity ratios also indicate near-term resources exceed near-term obligations, while profitability and quality screens remain constructive.
The constraint is leverage. Debt substantially exceeds cash and investments, and cash remains below its level at the opening of the reported window despite the recent rebound. A revenue shortfall linked to reimbursement or coverage pressure would therefore matter beyond the income statement by reducing financial flexibility; management already assumes an exchange-subsidy expiration will weigh on revenue.
What should you watch next at Quest Diagnostics (DGX)?
Short answer · as of
The next earnings report is expected on Feb 9, 2027.
Research dated 2026-09-12.
Watch whether revenue can hold near its recent high while operating income and net income preserve their latest step upward. Cash conversion after capital spending is the useful cross-check: another strong accounting result accompanied by weaker operating cash would deserve scrutiny.
The scheduled earnings release should also clarify whether management’s raised outlook remains supported and whether the assumed exchange-subsidy drag is developing as expected. Separately, progress on the planned Michigan laboratory joint venture would test the stated launch timetable.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Quest Diagnostics compare with its peers?
Short answer
Quest Diagnostics's score ranks 5th of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Quest differs from businesses whose value rests on a narrow diagnostic product or research pipeline. It monetizes a broad testing and information network across patients, clinicians, hospitals, health plans, employers and insurers, with collection infrastructure and specialized brands extending its reach.
That breadth makes network throughput, service economics and cash conversion the relevant comparison points. Revenue concentration in Diagnostic Information Services also means the adjacent technology and insurance offerings diversify customer use cases more than they diversify the reported revenue base.
| Company | Price | Market value | Score |
|---|---|---|---|
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $646.87 Nov 18, 2026 | $18.1B | 92 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| Quest Diagnostics (DGX) — this page | $258.99 | $28.5B | 74 |
| $370.78 Nov 18, 2026 | $30.1B | 71 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $245.00 – $262.00
- Consensus target
- $256.17
- Median target
- $260.00
Consensus record · Captured .
Measured against a quoted price of $258.99 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 13, 2026
- Transactions
- 57
- Identified insiders
- 15
- Purchases
- 0
- Sales
- 18
- Other transactions
- 39
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held DGX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported DGX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Quest Diagnostics (DGX) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Quest Diagnostics sell beyond routine laboratory tests?
Quest also provides advanced clinical and anatomic pathology testing, diagnostic information, insurance risk assessment and healthcare technology services through brands including AmeriPath, Dermpath Diagnostics, ExamOne and Quanum.
What is Quest Diagnostics planning for its Michigan laboratory operation?
Management said it expects to build the Michigan laboratory into a joint venture and is targeting a launch in the coming year. Progress against that timetable is the concrete item to monitor.
Why does the exchange-subsidy expiration matter to Quest Diagnostics?
Management has incorporated an expected revenue drag from the subsidy expiration into its outlook. The next earnings update can show whether that assumption remains appropriate or requires revision.
Has Quest Diagnostics maintained its recently increased dividend?
The declared upcoming payment matches the latest paid amount, which was above the earlier run rate. That establishes continuity at the increased level without indicating what later declarations may be.
What is the DGX stock price today?
The last price recorded for Quest Diagnostics Incorporated (DGX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the DGX price target?
The analyst consensus price target for Quest Diagnostics Incorporated (DGX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold DGX
Funds in our ETF coverage that list DGX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| IHF ETF | 3.98% | |
| XHS ETF | 2.33% |